title: Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).
authors.affiliation: Sankara Eye Hospital, Bangalore, India.
authors.forename: Mahesh P
authors.initials: MP
authors.lastname: Shanmugam
authors.affiliation: Sankara Eye Hospital, Bangalore, India. Electronic address: kaustubh.harshey@gmail.com.
authors.forename: Kaustubh B
authors.initials: KB
authors.lastname: Harshey
authors.affiliation: Sankara Eye Hospital, Bangalore, India.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Ramanjulu
authors.affiliation: Sankara Eye Hospital, Bangalore, India.
authors.forename: Divyansh K
authors.initials: DK
authors.lastname: Mishra
mesh_terms: D000068258:Bevacizumab; D006801:Humans; D008269:Macular Edema; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab